GeneDx may have more room to run even with its monstrous gains over the past year, according to Amy Zhang, Alger's executive vice president and small-cap portfolio manager. She joined CNBC's " Power Lunch " on Wednesday to give her insights on the health-care name and two more under-the-radar stock stories on Wall Street. Here is what Zhang said during the day's "Three-Stock Lunch." GeneDx Shares of GeneDx have soared 1,000% over the past 12 months, and Zhang thinks the genetic testing company is a standout name in the space that can grow even more. "They can do it fast and cheaper than their competitors while still having very high accuracy," the portfolio manager said. "They are really solving a very critical problem in health care, and we think the company still has a very long runway for growth." WGS 1Y mountain WGS, 1-year Zhang also believes its total addressable market, or TAM, could reach more than $40 billion. "Going forward, we're very positive it can continue to deliver robust revenue profitability growth," Zhang added. Natera Similar to GeneDx, genetic testing name Natera could face "tremendous growth ahead," Zhang said. The company's crown jewel is Signatera, its cancer monitoring test, she said. "Overall long term, we think the addressable market can be about $60 billion," the portfolio manager revealed during the segment. "Management's execution is superb and second to none." While Natera has fallen almost 7% over the past month, it has surged more than 66% over the past year. Glaukos For Glaukos , Zhang pointed to the company's launch of its iDose product , a sustained-release implant that aims to reduce fluid pressure in the eye, a condition that can lead to vision loss. "We think this is a game changer and has blockbuster potential," she said. Shares of Glaukos have shed more than 32% over the past three months but have gained nearly 15% over the past year.
